A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Standard Risk Or Down Syndrome B Lymphoblastic Leukemia (b-all) And Localized B-lymphoblastic Lymphoma (b-lly)
-
Age: Between 1 Year(s) - 31 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) B-ALL patients without DS must have an initial white blood cell count <50,000/µL. 2) B-ALL patients with DS are eligible regardless of the presenting white blood cell count.
You may not be eligible for this study if the following are true:
-
1) Patient must not have secondary ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy. 2) Patient must not have acute undifferentiated leukemia(AUL
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.